On Thursday, India's Biocon Ltd in partnership with Abu Dhabi-based Company Neopharma, launched a drug for cancer, in Abu-Dhabi.

Chairman and Managing Director of Biocon Kiran Mazumdar-Shaw informed, "The drug is going to change the way breast cancer is treated through chemotherapy as it is a combination of chemotherapy and a biotech formulation. As it uses nanotechnology and a protein, it allows you to deliver a very cyto-toxic agent in a much targeted way to the tumour and will hence make a huge difference to cancer patients."

An understanding of proteins, led to transformation of her company's focus from an industrial enzymes manufacturer to biopharmaceuticals.

She revealed, "When we started seeing what else we could do using the technologies that we had developed for enzymes, biopharmaceuticals became a natural extension. The whole business of biopharmaceuticals was very different from industrial enzymes."

"I ventured into biotechnology because of my passion for the biological sciences when nothing was happening in this field. It has taken me 30 years to really build a company that is now world renowned. So it has been a very satisfying journey and of course I still have got a long way to go," she added while discussing her own journey from a master brewer to a successful businesswoman.